Promising therapeutic agents for the treatment of Parkinson’s disease
Open accessAbstract
INTRODUCTION: The therapeutic management of Parkinson's disease has not yet been fully resolved, with motor fluctuations and levodopa-induced dyskinesia representing special therapeutic challenges. Furthermore, no disease-modifying therapies are currently available. AREAS COVERED: This review focuses on promising novel therapies that are at present under investigation in Phase I or Phase II trials. Special emphasis is placed on gene therapies: vectors, the utilized gene constructs and the side-effects. Moreover, the main risk factors of the gene therapy (the insertional mutagenesis, the uncontrolled overproduction of the expressed protein and the autoimmune and inflammatory responses) are described. EXPERT OPINION: Gene therapies represent a promising field in the therapeutic palette. In order to mitigate the side-effects of this therapy, the developments focus on the vectors applied. Gene therapy appears to be promising candidate for the management of motor complications in advanced stages of Parkinson's disease. In addition to dopamine replacement therapy, this field may also offer a solution for neurogenesis and neuroprotection.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Only adenosine A2A antagonists show promising results in the management of motor complications in advanced stages of Parkinson's disease.
“Out of these several approaches, only adenosine A2A antagonists show promising results in the management of motor complications in advanced stages of PD.”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188 · see citing works
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053 · see citing works
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290 · see citing works
Two genes encode distinct glutamate decarboxylases
Erlander, M. G., Tillakaratne, N. J. K., Feldblum, S., Patel, N., & Tobin, A. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90077-d · Cited by 1,213 · see citing works
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067 · see citing works
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
de la Fuente‐Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. (2001) · Science · doi:10.1126/science.1060937 · Cited by 991 · see citing works
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzmán, J. N., Ilijić, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 899 · see citing works
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C., Jankovic, J. J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M. A., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 816 · see citing works
Marks, W. J., Bartus, R. T., Siffert, J. O., Davis, C. S., Lozano, A. M., Boulis, N. M., Vitek, J. L., Stacy, M. A., Turner, D. A., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 685 · see citing works
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681 · see citing works
Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study
Schrag, A., Horsfall, L., Walters, K., Noyce, A., & Petersen, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70287-x · Cited by 674 · see citing works
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596 · see citing works
Peripheral cytokines profile in parkinson’s disease
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547 · see citing works
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 452 · see citing works
Safety and tolerability of putaminal <i>AADC</i> gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445 · see citing works
Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W. J., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., & Harvey-White, J. D. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7408 · Cited by 406 · see citing works
Results from a phase I safety trial of <i>hAADC</i> gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · see citing works
LeWitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P., Mori, A., Chaikin, P., Sussman, N. M., & 6002‐US‐005 Study Group (2008) · Annals of Neurology · doi:10.1002/ana.21315 · Cited by 358 · see citing works
Personality, Addiction, Dopamine: Insights from Parkinson's Disease
Dagher, A., & Robbins, T. W. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.031 · Cited by 339 · see citing works
Dopamine release in human ventral striatum and expectation of reward.
de la Fuente-Fernández, R., Phillips, A., Zamburlini, M., Sossi, V., Calne, D., Ruth, T. J., & Stoessl, A. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00130-4 · Cited by 329 · see citing works
Adenosine A 2A receptor antagonist treatment of Parkinson’s disease
Bara‐Jimenez, W., Sherzai, A. Z., Dimitrova, T. D., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., & Chase, T. N. (2003) · Neurology · doi:10.1212/01.wnl.0000073136.00548.d4 · Cited by 328 · see citing works
Åkerud, P., Canals, J. M., Snyder, E. Y., & Arenas, E. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08108.2001 · Cited by 303 · see citing works
Randomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PD
Hauser, R. A., Hubble, J. P., Truong, D. D., & the Istradefylline US-001 Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000081227.84197.0b · Cited by 300 · see citing works
Olanow, C. W., Bartus, R. T., Baumann, T. L., Factor, S. A., Boulis, N. M., Stacy, M. A., Turner, D. A., Marks, W. J., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287 · see citing works
Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sánchez‐Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W. C., Reutter, B. W., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.005 · Cited by 282 · see citing works
Grondin, R., Zhang, Z., Ai, Y., Cass, W. A., Maswood, N., Andersen, A. H., Elsberry, D. D., Klein, M. C., Gerhardt, G. A., & Gash, D. M. (2002) · Brain · doi:10.1093/brain/awf234 · Cited by 280 · see citing works
L‐type calcium channel blockers and Parkinson disease in Denmark
Ritz, B. R., Rhodes, S. L., Qian, L., Schernhammer, E. S., Olsen, J. H., & Friis, S. (2009) · Annals of Neurology · doi:10.1002/ana.21937 · Cited by 274 · see citing works
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Ilijić, E., Guzmán, J. N., & Surmeier, D. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.007 · Cited by 260 · see citing works
Pathophysiology of Parkinson's Disease: The MPTP Primate Model of the Human Disorder
Wichmann, T., & DeLong, M. R. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07477.x · Cited by 255 · see citing works
Mitochondrial dysfunction in Parkinson's disease
Greenamyre, J. T., MacKenzie, G. M., Peng, T., & Stephans, S. E. (1999) · Biochemical Society Symposia · doi:10.1042/bss0660085 · Cited by 248 · see citing works
Use of antihypertensives and the risk of Parkinson disease
Becker, C., Jick, S. S., & Meier, C. R. (2008) · Neurology · doi:10.1212/01.wnl.0000303818.38960.44 · Cited by 230 · see citing works
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Bartus, R. T., Baumann, T. L., Siffert, J. O., Herzog, C. D., Alterman, R. L., Boulis, N. M., Turner, D. A., Stacy, M. A., Lang, A. E., Lozano, A. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182904faa · Cited by 216 · see citing works
Palfi, S., Leventhal, L., Chu, Y., Ma, S. Y., Emborg, M. E., Bakay, R. A. E., Déglon, N., Hantraye, P., Aebischer, P., & Kordower, J. H. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-12-04942.2002 · Cited by 215 · see citing works
Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms
Levy, R. (2001) · Brain · doi:10.1093/brain/124.10.2105 · Cited by 191 · see citing works
Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study
Mizuno, Y., Hasegawa, K., Kondo, T., Kuno, S., Yamamoto, M., & The Japanese Istradefylline Study Group (2010) · Movement Disorders · doi:10.1002/mds.23107 · Cited by 188 · see citing works
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186 · see citing works
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
Stacy, M. A., Silver, D. E., Mendis, T., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313834.22171.17 · Cited by 182 · see citing works
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease
Feigin, A., Kaplitt, M. G., Tang, C., Lin, T., Mattis, P., Dhawan, V., During, M. J., & Eidelberg, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706006104 · Cited by 181 · see citing works
AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
Berg, D., Godau, J., Trenkwalder, C., et al. (2011) · Movement Disorders · doi:10.1002/mds.23616 · Cited by 175 · see citing works
Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
Bartus, R. T., Weinberg, M. S., & Samulski, R. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.281 · Cited by 165 · see citing works
Rosenblad, C., Kirik, D., & Björklund, A. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7296 · Cited by 161 · see citing works
Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects
Ai, Y., Markesbery, W. R., Zhang, Z., Grondin, R., Elseberry, D., Gerhardt, G. A., & Gash, D. M. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10689 · Cited by 149 · see citing works
[Alpha-synuclein in Parkinson's disease].
Oczkowska, A., Kozubski, W. P., & Dorszewska, J. (2014) · PubMed · Cited by 147 · see citing works
Grondin, R., Cass, W. A., Zhang, Z., Stanford, J. A., Gash, D. M., & Gerhardt, G. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-05-01974.2003 · Cited by 134 · see citing works
Emborg, M. E., Carbon, M., Holden, J. E., During, M. J., Ma, Y., Tang, C., Moirano, J. M., Fitzsimons, H. L., Roitberg, B. Z., Tüccar, E., et al. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600364 · Cited by 134 · see citing works
Hauser, R. A., Olanow, C. W., Kieburtz, K. D., Pourcher, E., Axelerad, A. D., Lew, M., Kozyolkin, О. А., Neale, A. C., Resburg, C., Meya, U., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70148-6 · Cited by 132 · see citing works
Trophic Factor Gene Therapy for Parkinson's Disease
Kordower, J. H., & Björklund, A. (2013) · Movement Disorders · doi:10.1002/mds.25344 · Cited by 129 · see citing works
Genetics of Parkinson's disease: the yield
Spatola, M., & Wider, C. W. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70011-7 · Cited by 127 · see citing works
Pathophysiologic basis of surgery for Parkinson's disease.
Obeso, J. A., Rodríguez-Oroz, M. C., Rodriguez, M., Macıás, R., Álvarez, L., Guridi, J., Vitek, J. L., & DeLong, M. R. (2000) · PubMed · Cited by 126 · see citing works
Placebo influences on dyskinesia in Parkinson's disease
Goetz, C. G., LASKA, E. M., Hicking, C., Damier, P., Müller, T. H., Nutt, J. G., Olanow, C. W., Rascol, O., & Russ, H. (2008) · Movement Disorders · doi:10.1002/mds.21897 · Cited by 123 · see citing works
Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
Dragicevic, E., Pötschke, C., Duda, J., Schlaudraff, F., Lammel, S., Schiemann, J. M., Fauler, M., Hetzel, A., Watanabe, M., Luján, R., et al. (2014) · Brain · doi:10.1093/brain/awu131 · Cited by 121 · see citing works
Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
Fernandez, H. H., Greeley, D. R., Zweig, R. M., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.06.008 · Cited by 117 · see citing works
Colosimo, C., Martínez‐Martín, P., Fabbrini, G., et al. (2010) · Movement Disorders · doi:10.1002/mds.23072 · Cited by 115 · see citing works
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
Rascol, O., Fox, S. H., Gasparini, F., Kenney, C., Paolo, T. D., & Gomez‐Mancilla, B. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.05.003 · Cited by 115 · see citing works
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?
Calabresi, P., Ghiglieri, V., Mazzocchetti, P., Corbelli, I., & Picconi, B. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0184 · Cited by 114 · see citing works
Parkinson Study Group (2013) · Movement Disorders · doi:10.1002/mds.25639 · Cited by 112 · see citing works
Glutamate, excitotoxicity, and programmed cell death in parkinson disease
Caudle, W. M., & Zhang, J. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.027 · Cited by 110 · see citing works
Grégoire, L., Morin, N., Ouattara, B., Gasparini, F., Bilbe, G., Johns, D. R., Vranesic, I., Sahasranaman, S., Gomez‐Mancilla, B., & Paolo, T. D. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.01.008 · Cited by 109 · see citing works
Nanocarriers in Gene Therapy: A Review
Xu, H., Li, Z., & Jin, S. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2044 · Cited by 106 · see citing works
Cunningham, L. A., & Su, C. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7877 · Cited by 103 · see citing works
Eslamboli, A., Cummings, R. M., Ridley, R. M., Baker, H. F., Muzyczka, N., Bürger, C., Mandel, R. J., Kirik, D., & Annett, L. E. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.007 · Cited by 103 · see citing works
Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study
Lee, Y., Lin, C., Wu, R., Lin, J., Chang, C., & Lai, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098961 · Cited by 99 · see citing works
Advances in non-dopaminergic treatments for Parkinson's disease
Stayte, S., & Vissel, B. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00113 · Cited by 98 · see citing works
Network modulation following sham surgery in Parkinson’s disease
Ko, J. H., Feigin, A., Mattis, P. J., Tang, C. C., Ma, Y., DHAWAN, V. M., During, M. J., Kaplitt, M. G., & Eidelberg, D. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75073 · Cited by 91 · see citing works
An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease.
Blandini, F. (2010) · PubMed · Cited by 90 · see citing works
Which dyskinesia scale best detects treatment response?
Goetz, C. G., Stebbins, G. T., Chung, K. A., Hauser, R. A., Miyasaki, J. M., Nicholas, A. P., Poewe, W. H., Seppi, K., Rascol, O., Stacy, M. A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25321 · Cited by 87 · see citing works
Guy, M. K., Page, R. L., Jensen, W. A., et al. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0230 · Cited by 84 · see citing works
Bartus, R. T., Kordower, J. H., Johnson, E. M., Brown, L., Kruegel, B. R., Chu, Y., Baumann, T. L., Lang, A. E., Olanow, C. W., & Herzog, C. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.023 · Cited by 82 · see citing works
Branch, S. Y., Sharma, R. V., & Beckstead, M. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4228-13.2014 · Cited by 79 · see citing works
Gene Therapy in Parkinsonʼs Disease
Feng, L., & Maguire‐Zeiss, K. A. (2010) · CNS Drugs · doi:10.2165/11533740-000000000-00000 · Cited by 78 · see citing works
Protection of nigral neurons by GDNF-engineered marrow cell transplantation
Park, K. W., Eglitis, M. A., & Mouradian, M. M. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(01)00242-5 · Cited by 71 · see citing works
Valles, F. E., Fiandaca, M. S., Eberling, J. L., Starr, P. A., Larson, P., Christine, C. W., Forsayeth, J., Richardson, R. M., Su, X., Aminoff, M. J., et al. (2010) · Neurosurgery · doi:10.1227/neu.0b013e3181f53a5c · Cited by 71 · see citing works
Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach
Szabó, N., Kincses, Z. T., Toldi, J., & Vécsei, L. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.021 · Cited by 68 · see citing works
Self-citationTolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
Simuni, T., Borushko, E., Avram, M. J., Miskevics, S. A., Martel, A., Zadikoff, C., Videnović, A., Weaver, F. M., Williams, K., & Surmeier, D. J. (2010) · Movement Disorders · doi:10.1002/mds.23308 · Cited by 65 · see citing works
Calcium channel blockers and β-blockers in relation to Parkinson's disease
Ton, T. G. N., Heckbert, S. R., Longstreth, W. T., Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith‐Weller, T., & Checkoway, H. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.08.011 · Cited by 51 · see citing works
Chen, W., Wang, H., Wei, H., Gu, S., & Wei, H. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.08.030 · Cited by 45 · see citing works
Gene-based Therapies in Parkinson’s Disease
Allen, P. J., & Feigin, A. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0233-2 · Cited by 40 · see citing works
Kynurenines in Parkinson’s disease: therapeutic perspectives
Zádori, D., Klivènyi, P., Toldi, J., Fülöp, F., & Vécsei, L. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0697-3 · Cited by 40 · see citing works
Self-citationSafinamide for the treatment of Parkinson's disease
Dézsi, L., & Vécsei, L. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.897694 · Cited by 37 · see citing works
Self-citationMavoglurant as a treatment for Parkinson’s disease
Petrov, D., Pedrós, I., de Lemos, M. L., Pallàs, M., Canudas, A. M., Lazarowski, A., Beas‐Zárate, C., Auladell, C., Folch, J., & Camins, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.931370 · Cited by 36 · see citing works
Extrapyramidal Symptoms Associated with Calcium-Channel Blockers
Daniel, J. R., & Mauro, V. F. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900113 · Cited by 32 · see citing works
Araki, K., Takino, T., Ida, S., et al. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb03249.x · Cited by 32 · see citing works
Manfredsson, F. P., Bloom, D. C., & Mandel, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.001 · Cited by 29 · see citing works
Novel therapeutic strategies in Parkinson’s disease
Klivènyi, P., & Vécsei, L. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0742-4 · Cited by 28 · see citing works
Self-citationAn Update on Gene Therapy in Parkinson’s Disease
Witt, J. L., & Marks, W. J. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0197-8 · Cited by 27 · see citing works
Therapeutic Potential of Targeting Metabotropic Glutamate Receptors for Parkinson’s Disease
Dickerson, J. W., & Conn, P. J. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.6 · Cited by 26 · see citing works
Novel therapy in Parkinson's disease: adenosine A2Areceptor antagonists
Szabó, N., Kincses, Z. T., & Vécsei, L. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.557066 · Cited by 24 · see citing works
Self-citationNMDA Antagonists as Parkinson's Disease Therapy: Disseminating the Evidence
Majláth, Z., & Vécsei, L. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.77 · Cited by 20 · see citing works
Self-citationSome molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease
Zádori, D., Szalárdy, L., Toldi, J., et al. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0930-8 · Cited by 18 · see citing works
Self-citationMental Disturbances in Parkinson's Disease and Related Disorders: The Role of Excitotoxins
Obál, I., Majláth, Z., Toldi, J., & Vécsei, L. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130294 · Cited by 16 · see citing works
Self-citationParkinsonian syndrome induced by amlodipine: Case Report
Teive, H. A. G., Germiniani, F. M. B., & Werneck, L. C. (2002) · Movement Disorders · doi:10.1002/mds.10185 · Cited by 16 · see citing works
Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs
Dézsi, L., & Vécsei, L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.878702 · Cited by 14 · see citing works
Self-citationEffects of Mitochondrial Toxins on the Brain Amino Acid Concentrations
Klivènyi, P., Kékesi, K. A., Hartai, Z., et al. (2005) · Neurochemical Research · doi:10.1007/s11064-005-8512-x · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504 · see citing works
- Authors
- Majláth, Z., Török, N., Toldi, J., & Vécsei, L.
- Affiliations
- University of Szeged (HU)
- Corresponding author
- Vécsei, László
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2016-03-30
- Volume
- 16
- Issue
- 6
- Pages
- 787-799
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2294701913
- Cited by
- 7
- References
- 94
- Citations by year
- 2024: 1 · 2023: 1 · 2020: 3 · 2019: 1 · 2016: 1
- FWCI
- 0.09
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Parkinson's disease, gene therapy, gene therapy vectors, insertional mutagenesis, autoimmunity, neurogenesis, neuroprotection, dopamine replacement therapy, motor fluctuations, levodopa-induced dyskinesia, disease-modifying therapy, novel therapeutic agents
- MeSH terms
- Animals, Antiparkinson Agents, Clinical Trials as Topic, Humans, Levodopa, Parkinson Disease, Genetic Therapy, Treatment Outcome, Adrenergic alpha-2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
